Beam Therapeutics is a biotech company dedicated to developing precision genetic medicines through a robust platform of gene editing technologies. Their primary focus is on base editing, a proprietary method that enables specific alterations to genomic sequences without causing double-stranded breaks in DNA, paving the way for a wide range of therapeutic applications. Beam is actively building internal manufacturing capabilities to support the advancement of their diverse portfolio of base editing programs. The company values cutting-edge science and aims to provide lifelong cures for patients facing serious diseases. With a commitment to teamwork and innovation, Beam fosters a collaborative environment that supports both the development of groundbreaking therapies and the growth of its employees.